BIOTON S.A. (BIO.WA)

PLN 2.98

(-0.83%)

Market Cap (In PLN)

255.44 Million

Revenue (In PLN)

181.63 Million

Net Income (In PLN)

2.27 Million

Avg. Volume

24.7 Thousand

Currency
PLN
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
2.88-3.775
PE
-
EPS
-
Beta Value
0.101
ISIN
PLBIOTN00029
CUSIP
-
CIK
-
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Jeremy Launders
Employee Count
-
Website
https://www.bioton.pl
Ipo Date
2005-03-31
Details
BIOTON S.A., a biotechnology company, develops, manufactures, markets, and sells pharmaceuticals, pharmaceutical preparations, pharmaceutical substances, medications, and other pharmaceutical products in Poland, China, Thailand, Vietnam, Libya, Argentina, Ukraine, Malta, Yemen, and the Russian Federation. The company offers recombinant human and classic insulin; oral anti-diabetic medication products; dietary supplements; strips for measuring sugar in blood, as well as OTC preparation for diabetics; diabetics drugs insulin vials and cartridges, including Gensulin N, Gensulin R, and Gensulin M30; GensuPen 2, an automatic injection system; and GensuCare glucometer, a diabetes monitoring technology, as well as needles. It engages in advertising, advisory, and company management activities. The company was founded in 1989 and is based in Ozarów Mazowiecki, Poland.